About
Takeda's annual report gives her birth year as 1970. She joined Shire in June 2016 as head of international value demonstration and access, and in May 2018 became head of its global hematology franchise. At Takeda she started in January 2019 as president of the Plasma-Derived Therapies Business Unit and has been a member of the Takeda Executive Team since then. From April 2022 she was president of the U.S. Business Unit. Whoo also has pages for leaders of other drug makers, such as Novartis CEO Vas Narasimhan and Novo Nordisk CEO Mike Doustdar.
Takeda's October 2026 semi-annual report lists her as Representative Director, President and CEO.
Whoo compiled this page from public sources: Takeda annual report (Form 20-F, 2026), Takeda news release, June 2026, BioSpace, January 2025, Takeda Form 6-K, October 2026. It is not affiliated with or endorsed by Julie Kim. Are you Julie Kim? Claim this page, or write to [email protected] to correct or remove it. Last updated: 2026-11-18.
Want a page like this? Create yours from your résumé.
Experience
Representative Director, President and Chief Executive Officer — Takeda
June 2026 – Present
- Succeeded Christophe Weber
- Also U.S. Country Head
President, U.S. Business Unit — Takeda
April 2022
President, Plasma-Derived Therapies Business Unit — Takeda
January 2019
Head of Global Hematology Franchise — Shire
May 2018
Head of International Value Demonstration and Access — Shire
June 2016
Education
Education
Not published in sources